Why is Mangalam Drugs falling/rising?

As of 15-Jul, Mangalam Drugs and Organics Ltd is experiencing a decline in its stock price, currently at 86.21, reflecting a decrease of 1.44 (-1.64%). The stock has underperformed its sector by 2.89% today, with a notable drop in delivery volume, which fell by 47.56% against the 5-day average. Over the past week, the stock has seen a slight decline of 1.14%, while it has performed better over the past month with a return of 7.76%. However, the stock's year-to-date performance is concerning, showing a significant drop of 25.65%. Despite a very attractive valuation indicated by a return on capital employed (ROCE) of 8.6 and a low PEG ratio of 0.1, the company has faced challenges, including a high debt to EBITDA ratio and a substantial decline in profit after tax, which fell by 97.6% compared to the previous four-quarter average.
In the broader market context, the stock's recent performance contrasts with the benchmark, as it has consistently underperformed against the BSE500 over the last three years. While the Sensex has shown a positive return of 5.67% year-to-date, Mangalam Drugs has struggled, with a year-to-date decline of 25.65%. This underperformance is compounded by weak long-term fundamentals, including a low average return on equity of 7.99% and a modest compound annual growth rate (CAGR) of 4.67% in operating profits over the last five years. The combination of these factors suggests that investor confidence may be waning, contributing to the stock's downward movement.